End-of-day quote
Shanghai S.E.
23:00:00 29/04/2024 BST
|
5-day change
|
1st Jan Change
|
14.3
CNY
|
+1.20%
|
|
+5.38%
|
-38.73%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
16,528
|
10,561
|
9,714
|
5,906
|
-
|
-
|
Enterprise Value (EV)
1 |
16,528
|
10,561
|
9,714
|
5,906
|
5,906
|
5,906
|
P/E ratio
|
71.2
x
|
60
x
|
53
x
|
28
x
|
22.8
x
|
18.9
x
|
Yield
|
-
|
0.18%
|
0.2%
|
0.7%
|
1.26%
|
-
|
Capitalization / Revenue
|
8.86
x
|
5.48
x
|
4.85
x
|
2.53
x
|
2.12
x
|
1.81
x
|
EV / Revenue
|
8.86
x
|
5.48
x
|
4.85
x
|
2.53
x
|
2.12
x
|
1.81
x
|
EV / EBITDA
|
42
x
|
32
x
|
27.9
x
|
15.3
x
|
12.9
x
|
11.2
x
|
EV / FCF
|
89,629,861
x
|
-
|
44,595,338
x
|
-
|
-
|
-
|
FCF Yield
|
0%
|
-
|
0%
|
-
|
-
|
-
|
Price to Book
|
9.22
x
|
5.37
x
|
3.96
x
|
2.25
x
|
2.06
x
|
1.86
x
|
Nbr of stocks (in thousands)
|
400,200
|
400,200
|
416,200
|
412,975
|
-
|
-
|
Reference price
2 |
41.30
|
26.39
|
23.34
|
14.30
|
14.30
|
14.30
|
Announcement Date
|
24/02/22
|
27/02/23
|
27/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
1,490
|
1,866
|
1,926
|
2,002
|
2,334
|
2,782
|
3,265
|
EBITDA
1 |
-
|
393.6
|
330
|
347.6
|
384.9
|
456.4
|
525.9
|
EBIT
1 |
-
|
246.5
|
212.5
|
214.1
|
257
|
314.5
|
377.6
|
Operating Margin
|
-
|
13.21%
|
11.03%
|
10.69%
|
11.01%
|
11.31%
|
11.57%
|
Earnings before Tax (EBT)
1 |
-
|
246.5
|
208.6
|
211.8
|
255
|
311.7
|
375.5
|
Net income
1 |
-
|
225
|
177.2
|
177.4
|
213.3
|
260.8
|
314.3
|
Net margin
|
-
|
12.05%
|
9.2%
|
8.86%
|
9.14%
|
9.38%
|
9.62%
|
EPS
2 |
0.1000
|
0.5800
|
0.4400
|
0.4400
|
0.5100
|
0.6267
|
0.7550
|
Free Cash Flow
|
-
|
184.4
|
-
|
217.8
|
-
|
-
|
-
|
FCF margin
|
-
|
9.88%
|
-
|
10.88%
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
46.85%
|
-
|
62.66%
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
81.96%
|
-
|
122.77%
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
0.0470
|
0.0470
|
0.1000
|
0.1800
|
-
|
Announcement Date
|
22/03/21
|
24/02/22
|
27/02/23
|
27/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
184
|
-
|
218
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
14.7%
|
9.43%
|
8.48%
|
8.17%
|
9.19%
|
9.84%
|
ROA (Net income/ Total Assets)
|
-
|
9.11%
|
6%
|
5.35%
|
5.5%
|
5.95%
|
6%
|
Assets
1 |
-
|
2,470
|
2,954
|
3,315
|
3,878
|
4,384
|
5,238
|
Book Value Per Share
2 |
-
|
4.480
|
4.910
|
5.890
|
6.350
|
6.930
|
7.680
|
Cash Flow per Share
2 |
-
|
0.7300
|
0.7600
|
0.8000
|
1.000
|
1.160
|
1.240
|
Capex
1 |
-
|
109
|
217
|
116
|
161
|
168
|
171
|
Capex / Sales
|
-
|
5.84%
|
11.28%
|
5.81%
|
6.91%
|
6.02%
|
5.24%
|
Announcement Date
|
22/03/21
|
24/02/22
|
27/02/23
|
27/02/24
|
-
|
-
|
-
|
Last Close Price
14.3
CNY Average target price
21.48
CNY Spread / Average Target +50.23% Consensus |
1st Jan change
|
Capi.
|
---|
| -38.73% | 816M | | -18.58% | 8.3B | | +47.25% | 3.78B | | -8.58% | 2.47B | | -38.71% | 2.46B | | -10.06% | 2.31B | | -5.44% | 1.95B | | -17.79% | 1.59B | | -40.78% | 1.21B | | +6.69% | 1.1B |
Medical & Diagnostic Laboratories
|